Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 78 out of 100. Treatments

Reviewed as evidence on: Low-dose aspirin x genetic profile and dementia incidence 2 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Plain-language summary

Objective To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. Methods Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia ("trigger") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification. Results A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups. Conclusions There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing. Classification of evidence This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. Clinicaltrialsgov identifier NCT01038583.

What this study adds

Evidence grade: High

This is a trial of 19,114 participants. The authors rate this as Class II evidence that low-dose aspirin does not significantly lower these risks in healthy older people. It does not show that aspirin causes harm, and it does not apply to people with heart disease or existing dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ryan, J., Storey, E., Murray, A. M., Woods, R. L., Wolfe, R., Reid, C. M., et al. (2020). Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. https://doi.org/10.1212/wnl.0000000000009277

Vancouver

Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020. doi:10.1212/wnl.0000000000009277. PMID: 32213642.

BibTeX

@article{ryan2020-32213642,
  author  = {Ryan, J. and Storey, E. and Murray, A. M. and Woods, R. L. and Wolfe, R. and Reid, C. M. and Nelson, M. R. and Chong, T. T. J. and others},
  title   = {{Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline}},
  journal = {Neurology},
  year    = {2020},
  doi     = {10.1212/wnl.0000000000009277},
  pmid    = {32213642},
  url     = {https://doi.org/10.1212/wnl.0000000000009277}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In ASPREE, a double-blind trial that randomly assigned 19,114 healthy adults aged 70 or older (65+ for US minorities) in the US and Australia to 100 mg of aspirin daily or a placebo, there was "no substantial difference" between the groups in dementia, probable Alzheimer's disease or mild cognitive impairment over a median 4.7 years (probable AD: hazard ratio 0.96, 95% CI 0.74–1.24). The authors rate this as Class II evidence that low-dose aspirin does not significantly lower these risks in healthy older people. It does not show that aspirin causes harm, and it does not apply to people with heart disease or existing dementia. The authors note that follow-up is still ongoing.

Study details

How this study scored 78/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 75 of the 96 points it could be judged on, which is 78 of 100. Total 78 of 100.75 of the 96 points we could judge = 78 of 100

Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 75 of the 96 points we could judge it on, which is 78 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 4 / 4 19,114 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 5 / 7 Cited 182 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 22.8 citations a year over 8 year(s) since 2020
Impact for its field and year 4 / 6 Cited 17.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 12 other studies in this library
Still being cited 3 / 4 Cited 73 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 1 / 3 University of Pittsburgh: institution h-index 1,470 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32213642)
Free to read 0 / 2 Behind a paywall — scores zero
Points 75 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 75 of the 96 points we could judge it on is 78 out of 100.
Total 78 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “aspirin-genotype-dementia”

2 studies in the library carry the topic tag “aspirin-genotype-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →